Restoring the Signal: NurExone Advances Optic Nerve Exosome Therapy

TORONTO and HAIFA, Israel – October 09, 2026

The human nervous system is a marvel of biological infrastructure, yet it suffers from a fatal design flaw: when its primary cables are severed, they do not easily repair themselves. As a commentator who frequently examines the structural integrity of the systems we rely on—from public health frameworks to urban grids—I often find the most compelling narratives at the intersection of biological vulnerability and technological intervention. Today, that intersection is illuminated by new data from the biopharmaceutical sector targeting one of the most unforgiving pathways in the human body: the optic nerve.

NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90), a company specializing in exosome-based regenerative therapies, has announced promising preclinical findings in its quest to reverse optic nerve damage. Conducted in collaboration with the Goldschleger Eye Institute at Sheba Medical Center in Israel, the study demonstrates that NurExone’s proprietary naïve exosomes and its lead pharmaceutical candidate, ExoPTEN, can preserve or restore retinal electrical activity following severe injury.

For decades, optic nerve damage—whether from traumatic injury or degenerative conditions like glaucoma—has been a one-way street to permanent vision loss. The mammalian central nervous system actively inhibits axonal regeneration, meaning the connection between the eye and the brain remains severed once broken. NurExone’s latest data suggests we may finally be developing the biological tools necessary to bypass these internal roadblocks.

The Science of Restoring the Signal

The recent study utilized a well-established optic nerve crush model in rats, a rigorous method where the nerve connecting the eye to the brain is deliberately injured to simulate severe trauma or compressive neuropathies. Researchers then compared uninjured eyes with injured eyes treated with a phosphate-buffered saline (PBS) control, NurExone’s naïve exosomes, and ExoPTEN.

To measure success, the team relied on electroretinography (ERG), a diagnostic test that captures the retina’s electrical response to light stimuli. The results were striking. At higher light intensities, the average response in the naïve exosome group reached approximately 5 microvolts (µV)—the study’s established threshold for a measurable retinal response.

However, it was the ExoPTEN-treated group that delivered the most compelling data. These treated eyes not only exceeded the 5 µV threshold but showed a statistically significant improvement in retinal response compared to the PBS-treated injured eyes (p = 0.04). In the strict parameters of preclinical research, a p-value of 0.04 indicates a high probability that the functional recovery is a direct result of the intervention rather than random chance.

“Diseases affecting the retina and optic nerve are among the leading causes of blindness and vision impairment worldwide,” noted Dr. Lior Shaltiel, Chief Executive Officer of NurExone. “We are seeing measurable retinal responses with our proprietary naïve exosomes following injury, and a statistically significant improvement with ExoPTEN compared with the control group at higher light intensities.”

The research was spearheaded by Prof. Ygal Rotenstreich, a leading figure in neuro-ophthalmology and retinal degeneration at Sheba Medical Center. “Optic nerve damage often leads to permanent vision loss because the connection between the eye and the brain has a very limited ability to repair itself,” commented Prof. Rotenstreich. “In this study, treated eyes showed clear, measurable retinal activity following injury. These preclinical findings support the continued development of a potential new treatment approach for serious vision-threatening conditions.”

A Dual-Track Strategy for Central Nervous System Repair

To understand the significance of these findings, one must look at the biological mechanics of NurExone’s platform. Exosomes are naturally occurring extracellular vesicles—microscopic nanocarriers that cells use to communicate and transfer proteins, lipids, and genetic material.

NurExone’s approach is two-fold. First, the study demonstrated that even the company's "naïve" exosomes—those without added therapeutic cargo—possess intrinsic biological activity capable of providing neuroprotective effects. Second, their lead candidate, ExoPTEN, engineers these exosomes to deliver small interfering RNA (siRNA) specifically designed to inhibit phosphatase and tensin homolog (PTEN).

PTEN is a critical inhibitor of the mTOR signaling pathway. By suppressing PTEN, ExoPTEN effectively removes the biological brakes that prevent neural regeneration, encouraging damaged neurons to survive and regrow. This mechanism is not limited to the optic nerve. ExoPTEN is simultaneously being developed for acute spinal cord injuries, where it has already demonstrated strong preclinical data and secured Orphan Drug Designation from both the FDA and EMA.

By targeting multiple indications within the central nervous system, NurExone is validating a platform technology rather than a single-use drug. This dual-track strategy significantly de-risks the clinical development pathway, proving that the exosome delivery system can successfully navigate different neural environments.

Navigating a Complex Competitive Landscape

The race to cure optic neuropathies is intensifying, with several distinct therapeutic modalities vying for dominance. Gene therapies are currently a major focus in the sector. Companies like Life Biosciences are advancing epigenetic reprogramming therapies, while academic institutions like the University of Cambridge are utilizing CRISPR and other gene-editing tools to stimulate the regeneration of damaged optic nerve fibers.

Concurrently, small molecule neuroprotective agents are making their way through the clinic. Oculis Holding AG, for instance, is advancing Privosegtor into registrational trials for optic neuritis, having shown promising anatomical preservation in Phase 2 trials.

NurExone’s exosome-based approach occupies a unique and potentially highly advantageous niche within this landscape. Unlike viral vectors used in many gene therapies, which can trigger immune responses or face manufacturing bottlenecks, exosomes are natural, biocompatible delivery vehicles. If NurExone can successfully scale its manufacturing, ExoPTEN could offer a targeted, minimally invasive regenerative therapy that avoids the systemic toxicity associated with some small molecules and the immunological hurdles of viral gene therapy.

The Financial Architecture of Preclinical Biotech

However, scientific brilliance must invariably interface with financial reality. Like most preclinical biotechnology firms, NurExone operates in a high-stakes environment characterized by significant cash burn and a reliance on continuous capital raises. Developing a novel therapeutic platform from the laboratory bench to commercial distribution is an enterprise that requires deep financial reserves.

Recognizing this, NurExone has been actively structuring its corporate foundation to support the long road ahead. The company recently issued a corrective disclosure regarding its investor awareness engagement with RedChip Companies, Inc., clarifying that the non-exclusive agreement is a 180-day contract beginning September 30, 2026, rather than the previously stated 90-day term. Such campaigns are vital for maintaining visibility in crowded capital markets, especially for a company listed on the TSX Venture Exchange.

More critically, NurExone is laying the groundwork for clinical-grade production. In August 2026, the company’s U.S. subsidiary, Exo-Top Inc., signed a binding memorandum of understanding with Made Scientific, Inc. to establish an exclusive U.S. Good Manufacturing Practice (GMP) exosome supply partnership. Targeting initial GMP batches in the first half of 2027, this manufacturing infrastructure is the critical bridge between preclinical promise and human trials.

With these positive rat model results in hand, NurExone is now preparing to advance its optic nerve injury program into larger-animal studies, specifically a planned rabbit model. This next phase will be pivotal for evaluating dosing, delivery methods, tolerability, and safety in an eye structure more closely resembling that of a human. As the company finalizes protocols and secures the necessary funding and regulatory approvals for this larger study, the broader scientific community will be watching closely to see if the lights can finally be turned back on for patients suffering from irreversible nerve damage.